Data Integrity, Lab Control Issues Lead to 483s for Two Manufacturers Post author:Sam Post published:February 12, 2017 Post category:Drug GMP Report The FDA issued Form 483s to two drug manufacturers for data integrity and laboratory issues. Source: Drug GMP Report You Might Also Like EMA Suspends Generics Tested at Mumbai Lab September 10, 2020 Warning Letter Roundup: Facilities Slammed for CGMP Violations November 8, 2018 FDA and NIIMBL Team Up on Advanced Manufacturing September 11, 2019